Not all sufferers with CLL involve therapy. Even with all current improvements, the iwCLL still suggests watchful observation for sufferers with asymptomatic sickness.86 This suggestion relies on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 Both tr